The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
Researchers find a 23% increased risk of death among patients who received a transfusion during surgery or post-operative hospitalization.
Increased perinephric fat is associated with increased blood loss and operative time, study shows.
The estimated recurrence rate at 10 years was 88.3%, data show.
Seventeen percent of Americans think that there is nothing people can do to change their risk.
Benefits in cancer-linked symptoms mediated by lower Impact of Event Scale one month after intervention.
Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.
ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.
Death from PCa is down 45% from peak rates, but more than 29,000 men are projected to die from PCa in 2014.
The five-year cancer-specific and overall survival rates were 100% and 97.8%, respectively.
Renal tissue could one day be created that would be functional as well as completely immunocompatible.
Active smoking shortens progression-free and overall survival, study finds.
Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Patients aged 75-79 who had localized tumors had worse cancer-specific survival with nonsurgical management than surgery.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
